FTC seeks more information in MiMedx-Sanara merger review
The Federal Trade Commission issued a Second Request to MiMedx Group and Sanara MedTech on October 15, 2026, seeking additional information for its antitrust review. The request keeps the waiting period open until 30 days after substantial compliance by the companies, potentially pushing completion past the parties’ year-end target. MiMedx’s proposed cash-and-stock acquisition values Sanara at $35 per share, with Sanara investors receiving $33 in cash plus 0.4735 MiMedx shares for each share owned.
Why it matters
The FTC request extends the regulatory timetable and makes the merger’s closing date less certain for both companies. Sanara and MiMedx shares fell 5.5% and 2.8%, respectively, in the reported market reaction.
Key facts
- 1The FTC sent the Second Request on Oct 15, 2026. tradingview.com
- 2The HSR waiting period will continue until 30 days after substantial compliance, unless the FTC ends or extends it. tradingview.com
- 3MiMedx agreed in July to acquire Sanara in a cash-and-stock transaction valued at $35 per share. finance.yahoo.com
- 4Sanara shareholders are set to receive $33 in cash and 0.4735 MiMedx shares for every Sanara share they own. finance.yahoo.com
- 5The companies had expected the transaction to close by the end of the year. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.